{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:25Z","timestamp":1793061325299,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0112304"],"award-info":[{"award-number":["2020YFA0112304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172576"],"award-info":[{"award-number":["82172576"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159301"],"award-info":[{"award-number":["92159301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91959207"],"award-info":[{"award-number":["91959207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xcrm.2026.102977","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:39:04Z","timestamp":1786027144000},"page":"102977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision neoadjuvant treatment with AI-assisted subtyping in HR+\/HER2\u2212breast cancer: A randomized, phase 2 trial FASCINATE-N"],"prefix":"10.1016","volume":"7","author":[{"given":"Jun-Jie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Xiaoxi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Feng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen-Hong","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Da","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4577-5358","authenticated-orcid":false,"family":"Zhi-Ming Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102977_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102977_bib2","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102977_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103280","article-title":"Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: When, why and what?","volume":"160","author":"Torrisi","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2026.102977_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102669","article-title":"Neoadjuvant therapy in hormone Receptor-Positive\/HER2-Negative breast cancer","volume":"123","author":"Cantini","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2026.102977_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102977_bib6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med."},{"key":"10.1016\/j.xcrm.2026.102977_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nature medicine"},{"key":"10.1016\/j.xcrm.2026.102977_bib8","article-title":"The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102977_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102977_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","article-title":"Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy","volume":"183","author":"Krug","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102977_bib11","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","article-title":"Molecular classification of hormone receptor-positive HER2-negative breast cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102977_bib12","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","article-title":"Classification and mutation prediction from non\u2013small cell lung cancer histopathology images using deep learning","volume":"24","author":"Coudray","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102977_bib13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41586-024-07894-z","article-title":"A pathology foundation model for cancer diagnosis and prognosis prediction","volume":"634","author":"Wang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102977_bib14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/his.13760","article-title":"Artificial intelligence\u2014the third revolution in pathology","volume":"74","author":"Salto-Tellez","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.xcrm.2026.102977_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccell.2025.11.003","article-title":"Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+\/HER2\u2212 breast cancer: The LINUXtrial","volume":"44","author":"Fan","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102977_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cac2.12649","article-title":"A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+\/HER2- breast cancer-FINEST study","volume":"45","author":"Chen","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.xcrm.2026.102977_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225032","article-title":"Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial","volume":"16","author":"Zuo","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40265-024-02144-y","article-title":"Efficacy and Safety of CDK4\/6 Inhibitors: A Focus on HR+\/HER2\u2212 Early Breast Cancer","volume":"85","author":"Klocker","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2026.102977_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution \u2014 a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+\/HER2\u2212 Breast Cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102977_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.18.01624","article-title":"Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor\u2013Positive Early Breast Cancer: PALLET Trial","volume":"37","author":"Johnston","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejca.2022.01.014","article-title":"Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer","volume":"166","author":"Delaloge","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102977_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13058-025-01976-0","article-title":"Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+\/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study","volume":"27","author":"Zhang","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102977_bib25","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102977_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.annonc.2020.10.471","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","volume":"32","author":"Fasching","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: Results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102977_bib28","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1158\/0008-5472.CAN-24-5002","article-title":"Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+\/HER2- Breast Cancer","volume":"85","author":"Zhu","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102977_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2022.101818","article-title":"Association of Apatinib and Breast Cancer: A systematic review and meta-analysis","volume":"44","author":"Wang","year":"2022","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41392-025-02137-7","article-title":"Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial","volume":"10","author":"Shen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102977_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221118053","article-title":"Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial","volume":"14","author":"Yang","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ijc.34717","article-title":"Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis","volume":"154","author":"Liu","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102977_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102977_bib34","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102977_bib35","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-GS2-03","article-title":"Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer","volume":"83","author":"Bardia","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102977_bib36","article-title":"neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)\/HER2-negative (neg) early breast cancer (EBC)","volume":"31","author":"Oliveira","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102977_bib37","article-title":"SHR-A1811 as neoadjuvant treatment in patients with HR-positive, HER2-low breast cancer: the first-stage results from an open-label, single-arm, two-stage, phase II clinical trial","volume":"43","author":"Liu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib38","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamaoncol.2021.2132","article-title":"Neoadjuvant Endocrine Therapy in Clinical Practice: A Review","volume":"7","author":"Sella","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib40","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+\/HER2\u2013 Early Breast Cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib41","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO\u2013College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib42","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib43","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.xcrm.2026.102977_bib44","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1038\/s41467-023-42504-y","article-title":"Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102977_bib45","article-title":"Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network\u2013Based Artificial Intelligence Tool","volume":"7","author":"Krishnamurthy","year":"2023","journal-title":"JCO Clin. Cancer Inform."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:27:45Z","timestamp":1793060865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666379126003940"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102977","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision neoadjuvant treatment with AI-assisted subtyping in HR+\/HER2\u2212breast cancer: A randomized, phase 2 trial FASCINATE-N","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102977"}}